FDA Approves ILUMYA for Active Psoriatic Arthritis

The U.S. Food and Drug Administration (FDA) has approved a supplemental Biologics License Application for ILUMYA (tildrakizumab-asmn) to treat adults with active psoriatic arthritis. This decision expands the drug's use, which was previously cleared for a skin condition, to include a painful joint disease.